

RICT 2015

Drug Discovery and Selection

Confirmed Speakers

Confirmed Speakers

Covalent Kinase Inhibitors: A Practical Guide to Molecular Trapping



Dr Tjeerd BARF
(ACERTA PHARMA BV, Oss, The Netherlands)

Resistance Phenotypes and SAR in HCV Drug Development



Dr John BILELLO
(MERCK, Whitehouse Station, United States)

Shedding Light on Protein Kinase Plasticity



Prof. Pascal BONNET
(UNIVERSITY OF ORLÉANS, Orléans, France)

Chemical Probes for Epigenetic Proteins



Prof. Paul BRENNAN
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Two Steps Forward, One Step Back: Successes and Failures in Structure-based Discovery of GPCR Ligands



Prof. Jens CARLSSON
(STOCKHOLM UNIVERSITY, Stockholm, Sweden)

Discovery and Characterisation of Potent and Selective Inhibitors of ATR Kinase as Anti-cancer Agents



Mr Jean-Damien CHARRIER
(VERTEX PHARMACEUTICALS, OXON, United Kingdom)

Fragment and Structure-Based Drug Discovery for a Family C GPCR: Discovery of the mGlu5 NAM Pre-clinical Candidate HTL14242



Dr John CHRISTOPHER
(HEPTARES, Hertfordshire, United Kingdom)

Antibiotic Resistance is an Emerging Disease



Dr Patrice COURVALIN
(INSTITUT PASTEUR, Paris, France)

From in situ Click to in vivo: Effect of Inhibition of Insulin Degrading Enzyme

RICT 2015

Drug Discovery and Selection

Confirmed Speakers



Prof. Rebecca DEPRez-POULAIN
(UNIVERSITY OF LILLE, Lille, France)

Cerdelga, an Oral Therapy for Gaucher's Disease; from Discovery to Launch



Dr David J HARRIS
(SANOFI, Waltham, United States)

Retinoids/Steroids as Ligands for Pharmacological Chaperon and Protein Knockdown Approach



Prof. Yuichi HASHIMOTO
(THE UNIVERSITY OF TOKYO, Tokyo, Japan)

Lessons learned in TB Drug Discovery



Dr Jan JIRICEK
(NOVARTIS INSTITUTE FOR TROPICAL DISEASES, Singapore, Singapore)

BAY 1067197 - Discovery of a Partial Adenosine A1 Agonist for the Treatment of Heart Failure



Dr Daniel MEIBOM
(BAYER PHARMA, Wuppertal, Germany)

Novel Triazolopyridine Compounds as Selective JAK1 Inhibitors: From Target Discovery to Filgotinib



Dr Christel MENET
(GALAPAGOS, Brussels, Belgium)

Paul Ehrlich Awardee - The Synthetic Peptide P140, a Skilled Strategist and Manipulator of the Immune System



Dr Sylviane MULLER
(IBMC-CNRS, Strasbourg, France)

Revolutionary Idea Yielded SGLT2 Inhibitor Canagliflozin for Treatment of Type 2 Diabetes



Dr Sumihiro NOMURA
(MITSUBISHI TANABE PHARMA CORPORATION, Saitama, Japan)

Drugs, Targets, Diseases and the Druggable Proteome



Prof. Tudor I. OPREA
(UNIVERSITY OF NEW MEXICO, Albuquerque, United States)

Phenotypic Screening for the Discovery of Novel Molecules for Therapeutic Cardiac Regeneration

RICT 2015

Drug Discovery and Selection

Confirmed Speakers



Dr Alleyn T. PLOWRIGHT
(ASTRAZENECA, Mölndal, Sweden)

Pierre Fabre Awardee - Small Molecules, Big Players



Dr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France)

Sofosbuvir: A Breakthrough Curative Therapy for HCV



Dr Michael SOFIA
(TEKMIRA/ONCORE BIOPHARMA, Doylestown, PA, United States)

Synthetic Molecules for Cell Biology and Cell Therapy



Prof. Motonari UESUGI
(KYOTO UNIVERSITY, Kyoto, Japan)

Locking the Bioactive Conformation – Discovery of BAY 85-8501, a Potent Inhibitor of Human Neutrophil Elastase



Dr Franz VON NUSSBAUM
(BAYER PHARMA, Lyon, France)

Discovery of HIV Integrase Inhibitors



Dr John WAI
(WUXI APPTEC, Shanghai, China)

Short Communications

How do a Proapoptotic and a Cell Penetration Peptide work Together to kill Cancer Cells?



Dr Isabel ALVES
(UNIVERSITY OF BORDEAUX, Pessac, France)

Development of Unnatural Basic Amino Acids Leading to Orally-Active NPFF Receptor Antagonists Preventing Opioid-Induced Hyperalgesia during the Treatment of Acute or Chronic Pains



Dr Frédéric BIHEL
(CNRS / UNIVERSITY OF STRASBOURG, Illkirch, France)

Allosteric Inhibitors of p38 MAPK-MK2 Pathway for Selective Cancer Cell Killing

RICT 2015

Drug Discovery and Selection

Confirmed Speakers



Dr Lenka MUNOZ
(UNIVERSITY OF SYDNEY, Sydney, Australia)

Development of Novel Multi-Target Directed Ligands for Alzheimer's Disease: Identification of Donecopride



Prof. Christophe ROCHAIS
(UNIVERSITY OF CAEN, Caen, France)